DAM for Pharmaceuticals: Managing Regulated Content From MLR Review to Distribution

Key Takeaways:

• Digital asset management (DAM) for pharmaceuticals is a central, access-controlled library for promotional, medical, and brand content. It tracks each asset’s approval status, version, and expiry date.
• The main reason pharma teams adopt a DAM is compliance. It gives medical, legal, and regulatory (MLR) reviewers a clear record of what was approved and helps keep expired or unapproved materials out of circulation.
• A pharma DAM works best alongside the systems teams already use, such as a regulated content system for formal MLR sign-off, a CRM for field sales, and web platforms for delivery.

Between January 1 and September 8, 2025, the FDA posted only five enforcement letters over prescription drug promotion, according to ProPharma Group. In the third quarter of 2025, mostly after a September 9 crackdown on drug advertising, the FDA’s drug center sent more than 50 Warning Letters and more than 50 Untitled Letters about drug ads, as Covington & Burling reported. When regulators look this closely at promotional content, pharma teams need to know exactly which version of a sales aid or banner was approved, and where it’s being used.

Digital asset management for pharmaceuticals gives those teams one governed library for that content. Marketing, medical affairs, regulatory, and sales work from the same approved files, and each asset carries the metadata, permissions, and expiry dates needed to use it correctly.

This guide covers what a pharmaceutical DAM does, how it supports MLR review, which features matter, and how to roll one out.

In this article:

• What Is DAM for Pharmaceuticals?
• Why Pharmaceutical Companies Need a DAM
• How DAM Supports MLR Review and Regulatory Compliance
• Key Features to Look for in a Pharmaceutical DAM
• How DAM Fits With Veeva, CRM, and Other Pharma Systems
• How to Implement a DAM in a Pharmaceutical Company

What Is DAM for Pharmaceuticals?

DAM for pharmaceuticals is a digital asset management system set up around how drug and biotech companies create, review, and publish content. It stores the files, records who approved them and when, and controls who can use them and for how long.

Pharmaceutical asset management covers a wider range of content than most industries handle:

• Promotional materials for healthcare professionals (HCPs) and patients, such as detail aids, leave-behinds, email templates, banner ads, and TV spots.
• Medical and scientific content such as mechanism-of-action animations, congress posters, and medical information response documents.
• Brand and packaging assets such as logos, product imagery, label and carton artwork, and brand guidelines.
• Training and corporate content such as sales training modules, investor presentations, and recruitment materials.

The core functions are the same as any DAM: central storage, search, version control, and permissions. The difference is how much the approval record matters. In most industries, using an old logo is an embarrassment. In pharma, distributing a sales aid with an unapproved claim or outdated safety information can lead to regulatory action.

Teams in life sciences, biotech, and medical devices face similar review requirements, so most of this guide applies to them too. For a broader look at how other sectors use DAM, see our guide to the industries that rely on digital asset management.

Why Pharmaceutical Companies Need a DAM

Most pharma content problems start when the approved file and the file people actually use drift apart. Shared drives, email attachments, and agency file-sharing links make that easy, and the risk grows with every brand, market, and channel.

Unapproved or Expired Content Reaches the Field

A rep downloads a sales aid in March and keeps it on a tablet. In June, the prescribing information changes and the piece is withdrawn, but the local copy stays in use. A DAM gives everyone one source for the current approved version and can restrict access to a file on its expiry date, so the withdrawn piece stops being available through the library.

Review Records Are Scattered

When reviewer comments live in email threads and markup PDFs, rebuilding the history of a piece for an audit or an FDA request takes days. Keeping every version, comment, and decision attached to the asset makes that history easy to pull.

Global Teams Localize From the Wrong Source

Affiliates in each market adapt core materials to local regulations and languages. If they start from an outdated master, the error spreads into every translation. A central library with clear version labels gives each affiliate the right starting point and shows headquarters which local versions exist.

Sensitive Content Is Hard to Contain

Unreleased launch materials, clinical trial imagery, and pipeline presentations need tighter controls than finished brand assets. Folder- and role-based permissions limit each file to the teams and agencies that need it.

These problems grow with the size of the portfolio, which is why DAM for the pharmaceutical industry is usually an enterprise DAM decision, involving IT, compliance, and commercial teams together.

How DAM Supports MLR Review and Regulatory Compliance

MLR review is the process in which medical, legal, and regulatory reviewers check promotional content before it’s used. Medical confirms the claims match the evidence, legal checks for liability and trademark issues, and regulatory confirms the piece follows the approved labeling and applicable codes.

A DAM supports that process at each stage of an asset’s life:

1. Creation: Agencies and in-house designers upload drafts into a restricted folder, tagged with the brand, market, audience (HCP or patient), and a status such as “In review.”
2. Review: The draft moves through defined review stages. Reviewers comment and mark up the file, and the asset can’t advance until the current stage signs off.
3. Approval: The approved final is stored with its job code, approval date, and expiry or re-review date. Its status changes to “Approved” and it becomes visible to the teams allowed to use it.
4. Distribution: Field teams, affiliates, and web teams pull the approved file from the DAM or a portal instead of receiving copies by email.
5. Expiry or withdrawal: When the expiry date arrives or the piece is withdrawn, the DAM restricts access, updates its status, and keeps the full history for audits.

Regulatory Requirements a DAM Helps You Meet

In the U.S., companies with approved prescription drug applications must submit promotional materials to the FDA on Form FDA 2253 at the time of initial dissemination or publication. A DAM makes it easier to show which final version went out and when it was first used.

When electronic records fall under 21 CFR Part 11, the regulation calls for secure, computer-generated, time-stamped audit trails that record when records are created, changed, or deleted, and changes can’t obscure earlier entries (21 CFR 11.10). The same section also calls for limiting system access to authorized individuals and using system checks to enforce the permitted sequence of steps, which is what DAM permissions and staged review flows do. Outside the U.S., industry codes set similar rules. Under Clause 8 of the ABPI Code of Practice in the UK, promotional material must be certified before it’s issued, recertified at least every two years while it stays in use, and its certificates kept for at least three years after final use. That makes a traceable approval record and reliable expiry dates just as important for UK teams.

A DAM doesn’t make content compliant on its own. Your standard operating procedures (SOPs), reviewers, and validated systems do that. What a DAM provides is the structure that keeps those processes consistent: required metadata, enforced review order, access limits, and a searchable record of every decision. For more on setting those rules, see our guide to DAM governance.

Key Features to Look for in a Pharmaceutical DAM

The features that matter most in pharma are the ones that control what can be used, by whom, and until when. Search speed and a clean interface still count, but they won’t prevent a compliance issue.

Structured Metadata for Regulated Content

Free-text tags aren’t enough when reviewers need to filter by approval status or expiry date. Look for structured metadata with required fields and controlled values, for example:

• Brand, product, and therapeutic area
• Market, language, and audience (HCP or patient)
• Job code or material ID
• Approval status, approval date, and expiry or re-review date

A consistent asset taxonomy built on these fields keeps search results reliable as the library grows. Our guide to what metadata is covers the different types in more detail.

Version Control and Audit History

Every revision should be kept, labeled, and linked to the comments and decisions that produced it. Check whether the audit history records who viewed, downloaded, edited, and approved each asset, and whether you can export that history for an inspection.

Expiry Dates and Automated Withdrawal

Approved materials usually carry a re-review or expiry date. The DAM should flag assets as they near that date and restrict them once it passes. In Cloudinary Assets, for example, teams can set up asset expiration workflows that restrict an asset, update its status, and move it to an expired folder on its expiry date.

Granular Roles and Permissions

Agencies, affiliates, field teams, and reviewers need different access. Look for custom roles and folder-level permissions, plus single sign-on through your identity provider so access ends when someone leaves the company.

Controlled External Sharing

Partners and agencies often need a subset of approved content. Branded portals and share links should let you limit downloads, apply watermarks, and set expiry dates on the link itself.

Multi-Stage Review Workflows

Review flows should support several sequential stages, required approvers per stage, and reviewers from outside the organization. If you run formal MLR in another system, check that the DAM’s API can pass status updates back and forth.

Delivery to Websites and Apps

Approved images and videos often end up on HCP portals, patient websites, and in email. A DAM that also handles delivery can serve the approved file directly and resize it for each channel, so web teams don’t download and re-upload copies that fall out of sync.

Validation and Security Documentation

If any records in the DAM fall under Part 11 or GxP rules, ask vendors what validation documentation and security certifications they provide. Their answers will shape how your quality team classifies the system.

How DAM Fits With Veeva, CRM, and Other Pharma Systems

A pharma DAM rarely works alone. Most companies already run several systems that touch the same content, and the DAM’s job is to connect them without creating another set of copies.

The first row is where teams should be most careful. If a regulated content system is your system of record for MLR, decide which system owns the approval status and make the other one follow it. Two systems that both claim to hold the “approved” version is the problem you were trying to solve.

For help drawing the line between product data and media, see our guide to choosing PIM tools. Our overview of integrated DAM solutions covers connection patterns in more depth.

How to Implement a DAM in a Pharmaceutical Company

Pharma DAM projects stall most often on governance decisions, not software setup. Settle who owns metadata, approval status, and expiry rules before migrating a single file.

1. Map your content and its rules. List the asset types you manage, where they live today, who approves them, and how long approvals last in each market.
2. Bring compliance in early. Involve regulatory, quality, and IT from the start. They’ll decide whether the DAM holds regulated records, which determines your validation and SOP work.
3. Define the metadata schema. Agree on required fields, controlled values, and naming conventions for job codes. Test them on a sample of real assets before rolling them out.
4. Set roles and permissions. Define what agencies, affiliates, reps, and reviewers can see and do. Connect single sign-on so access follows your HR records.
5. Clean up before you migrate. Remove duplicates and withdrawn materials, and fill in missing approval data. Moving expired pieces into a new system recreates the old problem.
6. Pilot with one brand or market. Run a full cycle, from draft through approval to expiry, and fix gaps before expanding.
7. Train and measure. Train each group on the tasks they’ll actually do. Track search success, reuse of approved assets, review cycle time, and how often expired content is requested.

If you’re still comparing vendors, a structured DAM RFP helps you test each one against your compliance requirements. Our DAM implementation guide and DAM best practices cover rollout planning in more detail.

Putting a Pharma DAM to Work

Digital asset management for pharmaceuticals comes down to keeping the approved version of every asset easy to find and everything else out of reach. Structured metadata, enforced review stages, expiry automation, and tight permissions do most of that work, and a clear split between your DAM and any regulated content system keeps the approval record in one place.

Start with governance: who owns each field, who approves each content type, and what happens on the expiry date. Then choose a platform that can enforce those rules and deliver approved media to every channel your teams publish to.

Cloudinary Assets combines a governed media library with creative approval, expiry workflows, and delivery to websites and apps. Contact our team to see how it fits your pharma content workflow.

Frequently Asked Questions

Does a Pharmaceutical DAM Need to Be 21 CFR Part 11 Compliant?

It depends on what you store in it. If the DAM holds electronic records or signatures required by FDA regulations, Part 11 controls such as audit trails and validation apply. If formal MLR sign-off happens in a separate validated system, your quality team may classify the DAM differently.

What Types of Assets Do Pharma Companies Manage in a DAM?

Common pharma assets include HCP and patient promotional materials, sales training modules, medical education content, congress posters, packaging and label artwork, brand guidelines, and corporate imagery.